^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MCF2L-AS1 (MCF2L Antisense RNA 1)

    i
    Other names: MCF2L-AS1, MCF2L Antisense RNA 1, MCF2L Antisense RNA 1 (Non-Protein Coding), NONHSAG014247.2, HSALNG0099545, MCF2L-AS1
    Associations

    News

    Trials
    8ms
    Expression and clinical significance of MCF2L-AS1 in stomach adenocarcinoma. (PubMed, Clinics (Sao Paulo))
    The oncogene role of MCF2L-AS1 in STAD is mediated through the negative regulation of miR-503-5p, highlighting its potential as a prognostic marker and therapeutic target.
    Journal
    |
    MIR503 (MicroRNA 503) • MCF2L (MCF.2 Cell Line Derived Transforming Sequence Like) • MCF2L-AS1 (MCF2L Antisense RNA 1)
    over2years
    MCF2L-AS1/miR-874-3p/STAT3 feedback loop contributes to lung adenocarcinoma cell growth and cisplatin resistance. (PubMed, Heliyon)
    Intriguingly, STAT3 was subsequently confirmed as a transcription factor that binds to the MCF2L-AS1 promoter, thereby enhancing its transcription. The MCF2L-AS1/miR-874-3p/STAT3 feedback loop plays a significant role in LUAD cell growth and cisplatin resistance.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • MCF2L (MCF.2 Cell Line Derived Transforming Sequence Like) • MCF2L-AS1 (MCF2L Antisense RNA 1)
    |
    cisplatin
    over2years
    MCF2L-AS1 promotes the biological behaviors of hepatocellular carcinoma cells by regulating the miR-33a-5p/FGF2 axis. (PubMed, Aging (Albany NY))
    By modulating miR-33a-5p/FGF2, MCF2L-AS1 exerts a tumor-promotive function in HCC. The MCF2L-AS1-miR-33a-5p-FGF2 axis may provide new therapeutic targets for HCC treatment.
    Journal
    |
    FGF2 (Fibroblast Growth Factor 2) • MCF2L (MCF.2 Cell Line Derived Transforming Sequence Like) • MCF2L-AS1 (MCF2L Antisense RNA 1) • MIR33A (MicroRNA 33a)
    almost3years
    A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer. (PubMed, Molecules)
    The low-risk group could benefit more from immunotherapy and some chemotherapeutics than the high-risk group. The aging-related lncRNA signature can provide new perspectives and methods for early BC diagnosis and therapeutic targets, especially tumor immunotherapy.
    Journal • Tumor mutational burden • IO biomarker • Immune cell
    |
    TMB (Tumor Mutational Burden) • DLGAP1-AS1 (DLGAP1 Antisense RNA 1) • MAPT (Microtubule Associated Protein Tau) • OTUD6B (OTU Deubiquitinase 6B) • MAPT-AS1 (MAPT Antisense RNA 1) • MCF2L (MCF.2 Cell Line Derived Transforming Sequence Like) • MCF2L-AS1 (MCF2L Antisense RNA 1) • USP30-AS1 (USP30 Antisense RNA 1)
    3years
    A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis. (PubMed, Bioengineered)
    It works through positive feedback processes involving direct YAP binding and subsequent modulation of intracellular gene expression. Our findings add to our understanding of MCF2L-AS1 regulation and its potential as a therapeutic target in patients with this fatal cancer type.
    Journal
    |
    MCF2L (MCF.2 Cell Line Derived Transforming Sequence Like) • MCF2L-AS1 (MCF2L Antisense RNA 1)
    over3years
    SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis. (PubMed, J Gynecol Oncol)
    SP1-induced MCF2L-AS1 promoted ovarian cancer cisplatin-resistance through activation of IGF2/MEK/ERK pathway via interacting with IGF2BP1.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ANXA5 (Annexin A5) • MCF2L-AS1 (MCF2L Antisense RNA 1)
    |
    IGF2BP1 overexpression
    |
    cisplatin